Evidence map›Paper›PMID 32021122›Full record

ArticlePatient preference and adherence2020

Feasibility and Acceptability of an mHealth-Based Approach as an HIV Prevention Strategy Among People Who Use Drugs on Pre-Exposure Prophylaxis.

Roman Shrestha, Frederick L Altice, Elizabeth DiDomizio, Brian Sibilio, Yerina S Ranjit, Michael M Copenhaver

Open access · goldAbstract read
In one paragraph

Article in Patient preference and adherence, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. HIV and Substance Use Disorders.Infectious disease clinics of North America · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Roman ShresthaAasaman Nepal, HIV Prevention Group, Lalitpur, Nepal.
Frederick L AlticeSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0002-7860-693X
Elizabeth DiDomizioSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Brian SibilioDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA.
Yerina S RanjitSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Michael M CopenhaverDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA.
Yale University · USUniversity of Connecticut · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Secondary HIV Prevention and Adherence Among HIV-infected Drug UsersR01DA032290 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI COPENHAVER, MICHAEL · 2012 to 2016
$3.1M
Enhancing Health Outcomes Among HIV+ Substance AbusersK24DA017072 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2003 to 2012
$1.5M
Training in MHealth Prevention with MSMK01DA051346 · NIDA · YALE UNIVERSITY · PI SHRESTHA, ROMAN · 2020 to 2024
$862k
HIV Prevention and Adherence Among Priority Drug Using PopulationsK02DA033139 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI COPENHAVER, MICHAEL · 2013 to 2017
$697k
NCATS NIH HHS UL1 TR001863NIDA NIH HHS K01 DA051346NIDA NIH HHS K02 DA033139NIDA NIH HHS K24 DA017072NIDA NIH HHS R01 DA032290
6 · The paper itself

Abstract

introductionThere has been increasing interest in the use of mHealth technology in health care. To our knowledge, however, there is a lack of empirical evidence on the utilization of text messaging services (short message service; SMS) for HIV prevention among opioid-dependent people who use drugs (PWUD). As part of our formative work, we conducted an in-depth feasibility and acceptability study on the use of SMS reminders for HIV prevention in this risk group.

methodsForty HIV-negative, opioid-dependent PWUD who are currently taking pre-exposure prophylaxis (PrEP) were enrolled in the study. Participants received daily PrEP text reminders and weekly HIV risk reduction-related messages, which were developed using a user-centered approach. Participants were assessed at baseline and immediately post-intervention. Following the post-intervention assessment, participants completed an in-depth qualitative interview.

resultsFeasibility of text messaging service was high, as assessed by participants' willingness to receive text messages (100%), retention (95%), and successful delivery of text messages (97%). Results further showed that participants were satisfied and perceived the use of daily PrEP reminder text messages as valuable and acceptable [mean: 75.0 (range 0-100)]. Whereas, acceptability for the weekly text messages on HIV risk reduction was 60.3 (±15.6), with 58.3% recommending them for future use. Thematic data exploration revealed important information for understanding and refining SMS content as well as logistical preferences.

conclusionOur findings provide preliminary evidence of the feasibility and acceptability of a text messaging-based approach as a potential tool for primary HIV prevention to improve PrEP adherence and HIV risk reduction among this underserved population. HIV risk reduction text messages need further modifications to become more appealing, with participant feedback taken into consideration.

Indexed as

HIV risk behaviorsmobile technologyopioid use disorderpre-exposure prophylaxistext messaging

Identifiers

PMID32021122
PMCPMC6971384
OpenAlexW2999248194

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.